---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-008210"
form_type: "8-K"
ticker: null
cik: "0001621227"
company_name: "Adaptimmune Therapeutics PLC"
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:11:02.655107+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Adaptimmune Q1 net loss $48.5M; afami-cel PDUFA Aug 4; secures $125M debt

## Summary
- Revenue $5.7M (down from $47.6M YoY); net loss $48.5M vs profit $1.0M in Q1 2023.
- FDA PDUFA date for afami-cel BLA set for August 4, 2024; GMP and GCP inspections ongoing.
- Secured up to $125M debt financing with Hercules Capital; first $25M available at close.
- Lete-cel pivotal trial IGNYTE-ESO met primary efficacy endpoint; full analysis expected late 2024.
- Cash and cash equivalents $140.7M; cash runway extended into late 2025 with anticipated afami-cel revenues.

## SEC filing metadata
- accession: 0001558370-24-008210
- form_type: 8-K
- cik: 0001621227
- company_name: Adaptimmune Therapeutics PLC
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1621227/000155837024008210/0001558370-24-008210-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1621227/000155837024008210/adap-20240515x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-008210
- JSON: https://secwatch.observer/filing/0001558370-24-008210.json
- Plain text: https://secwatch.observer/filing/0001558370-24-008210.txt

## Key facts
- Earnings Releases
  Adaptimmune Therapeutics PLC reported first quarter ended March 31, 2024 results: revenue $5.7 million.
  - Period: first quarter ended March 31, 2024
  - Revenue: $5.7 million
  - Result: reported results
  source text: Revenue for the three months ended March 31, 2024, was $5.7 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1621227/000155837024008210/0001558370-24-008210-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.